Published in Am J Gastroenterol on April 01, 2005
Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction (2007) 3.08
Never injected, but hepatitis C virus-infected: a study among self-declared never-injecting drug users from the Amsterdam Cohort Studies. J Viral Hepat (2009) 0.82
HIV vaccine trial willingness among injection and non-injection drug users in two urban centres, Barcelona and San Francisco. Vaccine (2011) 0.81
Sexual transmission of HCV between spouses. Am J Gastroenterol (2005) 2.08
Telaprevir for previously treated chronic HCV infection. N Engl J Med (2010) 8.33
Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology (2006) 4.90
Burden of liver disease in the United States: summary of a workshop. Hepatology (2002) 4.00
An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med (2014) 3.04
Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology (2005) 2.63
Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology (2006) 2.62
Risk prediction of hepatocellular carcinoma in patients with cirrhosis: the ADRESS-HCC risk model. Cancer (2014) 2.26
Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease. Hepatology (2005) 2.24
PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transpl (2011) 1.85
Laboratory test results after living liver donation in the adult-to-adult living donor liver transplantation cohort study. Liver Transpl (2011) 1.59
Alcohol use and hepatitis C. Hepatology (2002) 1.55
Multicenter evaluation of the performance characteristics of the bayer VERSANT HCV RNA 3.0 assay (bDNA). J Clin Microbiol (2004) 1.55
Recipient-donor race mismatch for African American liver transplant patients with chronic hepatitis C. Liver Transpl (2012) 1.54
Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study. Transplantation (2003) 1.54
Hepatic steatosis at 1 year is an additional predictor of subsequent fibrosis severity in liver transplant recipients with recurrent hepatitis C virus. Liver Transpl (2011) 1.52
Trends in waiting list registration for liver transplantation for viral hepatitis in the United States. Gastroenterology (2009) 1.35
Outcomes of donor evaluation in adult-to-adult living donor liver transplantation. Hepatology (2007) 1.31
Specific human leukocyte antigen class I and II alleles associated with hepatitis C virus viremia. Hepatology (2010) 1.28
A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. Hepatology (2013) 1.21
Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection. Hepatology (2012) 1.20
Limitations of conventionally derived chronic liver disease mortality rates: Results of a comprehensive assessment. Hepatology (2008) 1.17
Prospective analysis of depression during peginterferon and ribavirin therapy of chronic hepatitis C: results of the Virahep-C study. Am J Gastroenterol (2009) 1.16
Hospitalization rates before and after adult-to-adult living donor or deceased donor liver transplantation. Ann Surg (2010) 1.13
New onset diabetes mellitus after liver transplantation: the critical role of hepatitis C infection. Liver Transpl (2004) 1.11
The changing epidemiology and natural history of hepatitis C virus infection. Clin Liver Dis (2006) 1.11
Hepatitis C virus-infected women have a higher risk of advanced fibrosis and graft loss after liver transplantation than men. Hepatology (2011) 1.09
Influence of cannabis use on severity of hepatitis C disease. Clin Gastroenterol Hepatol (2008) 1.08
Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. Am J Transplant (2005) 1.06
Treatment of hepatitis C in liver transplant patients: interferon out, direct antiviral combos in. Liver Transpl (2015) 1.01
Peginterferon pharmacokinetics in African American and Caucasian American patients with hepatitis C virus genotype 1 infection. Clin Gastroenterol Hepatol (2008) 1.00
Management of hepatitis B in liver transplant recipients. J Viral Hepat (2007) 0.99
Characteristics and management of patients with chronic hepatitis B in an integrated care setting. Dig Dis Sci (2014) 0.96
Management of posttransplant hepatitis C infection. Curr Opin Organ Transplant (2010) 0.94
Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infection. Gastroenterology (2013) 0.92
Hepatitis B virus quasispecies in hepatic and extrahepatic viral reservoirs in liver transplant recipients on prophylactic therapy. Liver Transpl (2011) 0.92
Projected future increase in aging hepatitis C virus-infected liver transplant candidates: a potential effect of hepatocellular carcinoma. Liver Transpl (2012) 0.91
Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol (2005) 0.91
The option of HBIG-free prophylaxis against recurrent HBV. J Hepatol (2012) 0.90
Rituximab therapy for pure red cell aplasia due to anti-epoetin antibodies in a woman treated with epoetin-alfa: a case report. J Med Case Rep (2009) 0.90
Protective antibody levels and dose requirements for IV 5% Nabi Hepatitis B immune globulin combined with lamivudine in liver transplantation for hepatitis B-induced end stage liver disease. Liver Transpl (2006) 0.88
Risk of advanced fibrosis with grafts from hepatitis C antibody-positive donors: a multicenter cohort study. Liver Transpl (2012) 0.88
Progression of biopsy-measured liver fibrosis in untreated patients with hepatitis C infection: non-Markov multistate model analysis. PLoS One (2011) 0.88
Telaprevir- and Boceprevir-based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease: A Multicenter Study. Transplantation (2015) 0.88
Clinical evaluation (Phase I) of a human monoclonal antibody against hepatitis C virus: safety and antiviral activity. J Hepatol (2006) 0.87
Sofosbuvir, simeprevir, and ribavirin for the treatment of hepatitis C virus recurrence in human immunodeficiency virus/hepatitis C virus-coinfected liver transplant recipients. Liver Transpl (2015) 0.86
Human immunodeficiency virus and liver transplantation: Hepatitis C is the last hurdle. Hepatology (2015) 0.86
Hepatitis C genotype influences post-liver transplant outcomes. Transplantation (2015) 0.85
The epidemiology and clinical characteristics of patients with newly diagnosed alcohol-related liver disease: results from population-based surveillance. J Clin Gastroenterol (2010) 0.85
Complementary and alternative medicine use in chronic liver disease patients. J Clin Gastroenterol (2010) 0.85
Ending vertical transmission of hepatitis B: the third trimester intervention. Hepatology (2014) 0.84
Donor Risk Index for African American liver transplant recipients with hepatitis C virus. Hepatology (2013) 0.84
Effects of ethnicity and socioeconomic status on survival and severity of fibrosis in liver transplant recipients with hepatitis C virus. Liver Transpl (2012) 0.83
Hepatitis C direct antiviral drugs and hepatic decompensation in patients with advanced cirrhosis: culprit or innocent bystander? Dig Dis Sci (2015) 0.83
Monocyte activation by interferon α is associated with failure to achieve a sustained virologic response after treatment for hepatitis C virus infection. J Infect Dis (2013) 0.82
Organ donors with positive viral serology or malignancy: risk of disease transmission by transplantation. Transplantation (2002) 0.82
Solid organ transplants in HIV-infected patients. Curr HIV/AIDS Rep (2013) 0.81
Restricting liver transplant recipients to younger donors does not increase the wait-list time or the dropout rate: the hepatitis C experience. Liver Transpl (2014) 0.80
Longitudinal effect of antiretroviral therapy on markers of hepatic toxicity: impact of hepatitis C coinfection. Clin Infect Dis (2004) 0.79
Long-term histological effects of preemptive antiviral therapy in liver transplant recipients with hepatitis C virus infection. Liver Transpl (2008) 0.79
Hepatitis C etiology of liver disease is strongly associated with early acute rejection following liver transplantation. Liver Transpl (2004) 0.79
Older donors: mounting risks for the hepatitis C-infected liver transplant recipient? Liver Transpl (2009) 0.79
Non-Markov multistate modeling using time-varying covariates, with application to progression of liver fibrosis due to hepatitis C following liver transplant. Int J Biostat (2010) 0.79
Bone Mineral Density, Bone Turnover, and Systemic Inflammation in Non-cirrhotics with Chronic Hepatitis C. Dig Dis Sci (2015) 0.78
Treatment of recurrent hepatitis C after liver transplantation. Clin Liver Dis (2005) 0.78
Management of patients co-infected with HBV and HCV. Expert Rev Anti Infect Ther (2009) 0.77
Management of hepatitis C-infected liver transplant recipients at large North American centres: changes in recent years. Clin Transplant (2006) 0.77
Sofosbuvir and ribavirin use in wait-listed patients with hepatitis C should be selective. Liver Int (2015) 0.77
Antiviral therapy in patients with chronic hepatitis B and cirrhosis. Gastroenterol Clin North Am (2004) 0.76
Should HCV-related cirrhosis be a contraindication for retransplantation? Liver Transpl (2003) 0.76
Reply to Prediction of hepatocellular carcinoma: using a complex risk model or assisting for smoking cessation? Cancer (2014) 0.75
High Rate of Hospital Admissions Among Patients with Cirrhosis Seeking Care in US Emergency Departments. Dig Dis Sci (2015) 0.75
Antiviral therapy in liver transplant recipients: is SVR the only endpoint that matters? J Hepatol (2007) 0.75
Individualizing hepatitis B infection prophylaxis in liver transplant recipients. J Hepatol (2011) 0.75
Chronic Hepatitis B. Curr Treat Options Gastroenterol (2004) 0.75
Kidney and liver transplantation in HIV-infected patients: case presentations and review. AIDS Patient Care STDS (2003) 0.75
Perspectives on treating hepatitis C infection in the liver transplantation setting. Curr Opin Organ Transplant (2016) 0.75
Understanding the natural history of chronic HBV and HCV infections. J Fam Pract (2010) 0.75
Is recurrent hepatitis C worse with living donors? Curr Opin Organ Transplant (2009) 0.75
Management of recurrent hepatitis C in liver transplant recipients. Infect Dis Clin North Am (2006) 0.75
Short Course of Postoperative Hepatitis B Immunoglobulin Plus Antivirals Prevents Reinfection of Liver Transplant Recipients. Transplantation (2017) 0.75
Prevalence and Predictors of Patient-Reported Long-Term Mental and Physical Health After Donation in the Adult to Adult Living Donor Liver Transplantation Cohort Study (A2ALL). Transplantation (2017) 0.75
Approach to the treatment-experienced patient with hepatitis C virus genotype 1 infection. Infect Dis Clin North Am (2012) 0.75
Sustained and focused hepatitis B virus nucleocapsid-specific T-cell immunity in liver transplant recipients compared to individuals with chronic and self-limited hepatitis B virus infection. Liver Transpl (2008) 0.75
Pretransplant severe hepatic encephalopathy, peritransplant sodium and post-liver transplantation morbidity and mortality. Liver Int (2011) 0.75